Nivalis Therapeutics Inc (NVLS)

2.49
0.01 0.40
NASDAQ : Health Care
Prev Close 2.50
Open 2.51
Day Low/High 2.42 / 2.52
52 Wk Low/High 3.68 / 20.43
Volume 224.54K
Avg Volume 627.50K
Exchange NASDAQ
Shares Outstanding 15.66M
Market Cap 40.24M
EPS -2.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

These 5 Stocks Under $10 Could Make You a Lot of Money

These 5 Stocks Under $10 Could Make You a Lot of Money

Here's a technical look at how to trade several under-$10 stocks triggering breakout trades.

Nivalis Therapeutics Announces Results From Phase 2 Clinical Trial Of Cavosonstat For Treatment Of Cystic Fibrosis

Nivalis Therapeutics Announces Results From Phase 2 Clinical Trial Of Cavosonstat For Treatment Of Cystic Fibrosis

Company to Host Conference Call Today, November 28, at 5:00 p.m. EST

Nivalis Therapeutics Reports Third Quarter 2016 Financial Results

Nivalis Therapeutics Reports Third Quarter 2016 Financial Results

Completion of Enrollment in Phase 2 Study of Cavosonstat for Treatment of Cystic Fibrosis Achieved During the Quarter

7 Stocks Under $10 Making Big Up Moves

7 Stocks Under $10 Making Big Up Moves

Here's a technical look at how to trade several under-$10 stocks that were making big moves to the upside recently.

7 Stocks Under $10 to Trade for Big Post-Brexit Gains

7 Stocks Under $10 to Trade for Big Post-Brexit Gains

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

Nivalis Therapeutics Reaches 50 Percent Enrollment Milestone In Phase 2 Clinical Trial In Cystic Fibrosis

Nivalis Therapeutics Reaches 50 Percent Enrollment Milestone In Phase 2 Clinical Trial In Cystic Fibrosis

Company on track to report results from the study in fourth quarter this year

Need For Patient-Centric Clinical Trials Fuels Adoption Of Greenphire's ClinCard Solution

Need For Patient-Centric Clinical Trials Fuels Adoption Of Greenphire's ClinCard Solution

Industry-leading patient reimbursement solution reaches milestone of 3 million transactions, totaling more than $200 million in patient reimbursements worldwide

Nivalis Therapeutics Announces FDA Fast Track Designation For N91115 In Patients With Cystic Fibrosis

Nivalis Therapeutics Announces FDA Fast Track Designation For N91115 In Patients With Cystic Fibrosis

N91115 is Currently in a Phase 2 Clinical Trial for Cystic Fibrosis, and Recently Received Orphan Drug Designation